Table 2.
Differences in patient characteristics according to whether grade 3 or higher thrombocytopenia occurred
| Variable | Description | 1:Grade 0–2 toxicities (n = 949) | 2:Grade 3–4 toxicities (n = 89) | Total (n = 1038) | p-value |
|---|---|---|---|---|---|
| Age |
Median [IQR] (min, max) |
Missing = 0 61.8 [54.2, 69.1] (19.4, 92) |
Missing = 0 59.7 [52.5, 68] (19.4, 85.1) |
missing = 0 61.4 [53.8, 69.1] (19.4, 92) |
0.0903 |
| Race | White | 881 (92.8%) | 79 (88.8%) | 960 (92.5%) | 0.2023 |
| Non-white | 68 (7.2%) | 10 (11.2%) | 78 (7.5%) | ||
| Sex | Male | 562 (59.2%) | 51 (57.3%) | 613 (59.1%) | 0.7363 |
| Female | 387 (40.8%) | 38 (42.7%) | 425 (40.9%) | ||
| Smoking status | No | 378 (39.8%) | 47 (52.8%) | 425 (40.9%) | 0.0237 |
| Yes | 571 (60.2%) | 42 (47.2%) | 613 (59.1%) | ||
| Type of immunotherapy | PD-1/L1 | 668 (70.4%) | 62 (69.7%) | 730 (70.3%) | 0.3949 |
| CTLA-4 | 181 (19.1%) | 13 (14.6%) | 194 (18.7%) | ||
| Combination PD-1/CTLA-4 | 68 (7.2%) | 9 (10.1%) | 77 (7.4%) | ||
| Other | 32 (3.4%) | 5 (6.7%) | 37 (3.6%) | ||
| Cancer type | Melanoma | 314 (33.1%) | 23 (25.8%) | 337 (32.5%) | 0.0003 |
| NSCLC + SCLC | 198 (20.9%) | 15 (16.9%) | 213 (20.5%) | ||
| RCC | 111 (11.7%) | 3 (3.4%) | 114 (11%) | ||
| Head and neck | 61 (6.4%) | 3 (3.4%) | 64 (6.2%) | ||
| Other | 265 (27.9%) | 45 (50.6%) | 310 (29.9%) | ||
| BMI |
Median [IQR] (min, max) |
Missing = 14 27.5 [23.4, 31.6] (13.4, 70.2) |
Missing = 2 29.1 [24.9, 33.5] (17, 50.2) |
Missing = 16 27.6 [23.6, 31.7] (13.4, 70.2) |
0.0107 |
| Line of therapy | Missing | 17 | 1 | 18 | 0.0789 |
| 1 | 342 (36.7%) | 27 (30.7%) | 369 (36.2%) | ||
| 2 | 280 (30%) | 21 (23.9%) | 301 (29.5%) | ||
| > = 3 | 310 (33.3%) | 40 (45.5%) | 350 (34.3%) |